Monocaprin Enhances Bioavailability of Fucoxanthin in Diabetic/Obese KK- Ay Mice

Mar Drugs. 2022 Jul 7;20(7):446. doi: 10.3390/md20070446.

Abstract

Fucoxanthin is a marine carotenoid found in brown seaweeds and several microalgae. It has been reported that fucoxanthin has health benefits such as anti-obesity and anti-diabetic effects. To facilitate fucoxanthin applications in the food industry, it is important to improve its low bioavailability. We attempted the combined feeding of fucoxanthin-containing seaweed oil (SO) and monocaprin in a powder diet and analyzed the fucoxanthin metabolite contents in the liver, small intestine and serum of diabetic/obese KK-Ay mice. After 4 weeks of feeding with the experimental diets, the serum fucoxanthinol concentrations of the mice fed 0.2% SO and 0.5% monocaprin were higher than those of the 0.2% SO-fed mice. Furthermore, fucoxanthinol accumulation in the liver and small intestine tended to increase in a combination diet of 0.2% SO and 0.125-0.5% monocaprin compared with a diet of 0.2% SO alone, although amarouciaxanthin A accumulation was not different among the 0.2% SO-fed groups. These results suggest that a combination of monocaprin with fucoxanthin-containing SO is an effective treatment for improving the bioavailability of fucoxanthin.

Keywords: bioavailability; fucoxanthin; fucoxanthinol; monocaprin.

MeSH terms

  • Animals
  • Biological Availability
  • Diabetes Mellitus*
  • Glycerides
  • Mice
  • Mice, Obese
  • Obesity / metabolism
  • Seaweed*
  • Xanthophylls

Substances

  • Glycerides
  • Xanthophylls
  • fucoxanthin
  • rac-glycerol 1-monodecanoate

Grants and funding

This work was supported by Taiyo Kagaku Co., Ltd.